Headquartered in Beijing, Prosperous Biopharma is a leading "Antibody Mimic" (AM) drug discovery and development company that artificially converts small, stable non-antibody proteins into targeted therapeutic drugs with similarly high antigen-binding ability as antibody drugs. Prosperous is committed to the production, research and development of biological fermentation methods to extract D-ribose, adenine, glutamine, arginine and other raw materials; currently it has international advanced biological fermentation extraction equipment technology and employs a number of biological doctors, who have returned from studying in the United States, and academicians of the Chinese Academy of Sciences as technical consultants. The production base is located in Jinji Town, Wuzhong City, Ningxia Hui Autonomous Region, covering an area of 135,200m², with a workshop area of 66,000m². The company also has established a product development center and a new retail-marketing center, which determined to wholeheartedly manufacture excellent products for the health of consumers. Compared to existing technologies, Prosperous Biopharma develops a computational-and-experimental platform that reduces the time of discovering and generating AM drug candidates from years to months, and from a few millions to less than a half million dollars. This ten-fold increase in efficiency, ten-fold decrease in cost, and a higher capacity to innovate - characteristics similar to the micro-processor revolution that spawned the information age. Prosperous Biopharma developed a unique business model to collaborate with some ex-China companies to generate AM drugs cost-effectively for the global market, in order to accumulate a fairly large portfolio of AM drug candidates in a short period of time which will be packaged and out-licensed to both domestic and international buyers or introduced into clinical trials. The fast turnover model has significantly mitigated the risks.